ICON has extensive experience in conducting gastrointestinal studies

We work across the across the entire drug development spectrum. Our experience ranges from the initial studies in Phase I through post-marketing efforts in Phase IV. In the past five years, there have been:

  • 80+

    Clinical gastrointestinal studies
  • 18,500+

    Patients
  • 3,600

    Sites worldwide

Our clinical trial experience includes but is not limited to the following gastrointestinal indications:

  • Acute Pancreatitis
  • Colorectal Conditions
  • Constipation
  • Crohn’s Disease
  • Inflammatory Bowel Disease
  • Irritable Bowel Disease
  • Diarrhea
  • Dyspepsia
  • Gastroenteritic Infections
  • Gastroesophageal Reflux
  • Liver Cirrhosis
  • Esophagitis
  • Ulcerative Colitis

Investigative sites

Our global investigator database includes over 1,500 gastrointestinal investigative sites across 50 countries.

We have worked with a wealth of specialty investigators in the areas of Abdominal Hernias, Anal and Rectal Conditions, Benign GI Neoplasms, Infections, Inflammations, Motility, Stenosis, Ulceration and Vascular Conditions, Diverticular Disorders, Exocrine Pancreatic Disorders, GI Hemorrhages, Malabsorption, Perotineal and Retroperitoneal Conditions, Salivary Gland Conditions, Tongue Conditions, and Oral Soft Tissue Conditions.

Gastrointestinal Therapeutic Area Group

ICON’s Gastrointestinal Therapeutic Area Group (TAG) is comprised of internal therapeutic specialists who are experienced in clinical research and drug development. The Gastrointestinal TAG contains networks with thought leaders, investigators, and clinical professionals throughout the world who are available to consult on individual projects.

In addition to providing support and guidance to the study team, the main responsibilities of the TAG teams include:

  • Global project feasibility
  • Protocol development, review and evaluation
  • Clinical trial planning
  • Therapeutic training and advice
  • Project oversight
  • Consulting, medical monitoring and advisory board representation
  • Interpretation of the clinical data
  • A 24-hour, global physician “on call” system to assure that no enrollment opportunity is missed